With 0.76 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.18 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $31.29 whereas the lowest price it dropped to was $28.2208. The 52-week range on CAI shows that it touched its highest point at $33.41 and its lowest point at $25.40 during that stretch. It currently has a 1-year price target of $33.00.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CAI was up-trending over the past week, with a rise of 2.44%, but this was up by 13.96% over a month. A look at the trailing 12-month EPS for CAI yields -10.43 with Next year EPS estimates of 0.17. For the next quarter, that number is -0.22. This implies an EPS growth rate of 19.50% for this year and 119.83% for next year.
Float and Shares Shorts:
At present, 277.93 million CAI shares are outstanding with a float of 114.87 million shares on hand for trading. On 2025-07-31, short shares totaled 1.29 million, which was 47.0 higher than short shares on 1751241600. In addition to Dr. David Dean Halbert M.D. as the firm’s Chairman, CEO & Founder, Mr. Brian J. Brille J.D. serves as its Executive Vice Chairman & Executive VP.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, CAI reported revenue of $120915000.0 and operating income of -$57951000.0. The EBITDA in the recently reported quarter was -$50421000.0 and diluted EPS was -$0.4.
Analysts Ratings:
In the same way, a target price assigned to a stock can also reveal much about its potential. With CAI analysts setting a high price target of 38.0 and a low target of 31.0, the average target price over the next 12 months is 32.875. Based on these targets, CAI could surge 25.79% to reach the target high and rise by 2.62% to reach the target low. Reaching the average price target will result in a growth of 8.82% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$10.18275 being high and -$10.69687 being low. For CAI, this leads to a yearly average estimate of -$10.43336. Based on analyst estimates, the high estimate for the next quarter is -$0.11 and the low estimate is -$0.2. The average estimate for the next quarter is thus -$0.16.
